Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: Radiographic observations

Knut N. Leknes, Jie Yang, Mohammed Qahash, Giuseppe Polimeni, Cristiano Susin, Ulf M E Wikesjö

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objectives: Effective carrier technologies and dosing appear critical for the successful use of bone morphogenetic proteins (BMPs). This study evaluated radiographically the potential of a purpose-designed titanium porous-oxide implant surface combined with recombinant human BMP-2 (rhBMP-2) to stimulate alveolar ridge augmentation. Material and methods: Twelve young-adult Labrador dogs were used. Three 10-mm titanium implants per jaw quadrant were placed 5 mm into the alveolar ridge following extraction of the premolar teeth and reduction of alveolar ridge. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml randomized to contralateral jaw quadrants. Another six animals received implants coated with rhBMP-2 at 3 mg/ml or uncoated control using the same split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately postsurgery (baseline), and at weeks 4 and 8 (end of study). Results: rhBMP-2-coated implants exhibited robust radiographic bone formation extending to and above the implant platform from week 4 (P<0.01). Some rhBMP-2-coated implants showed voids within the newly formed bone that gradually resolved and/or implant displacement, being severe in two animals receiving implants coated with rhBMP-2 at 3 mg/ml. Controls showed limited, if any, new bone formation at weeks 4 and 8 postsurgery. There were no significant differences among the rhBMP-2 groups in bone gain. Conclusions: The titanium porous-oxide surface serves as an effective carrier for rhBMP-2, showing a clinically significant potential to stimulate local bone formation. With the carrier technology used, therapeutic dosage appears to be in the range of 0.75-1.5 mg/ml.

Original languageEnglish (US)
Pages (from-to)1027-1033
Number of pages7
JournalClinical Oral Implants Research
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Alveolar Ridge Augmentation
Osteogenesis
Alveolar Process
Jaw
Technology
Newfoundland and Labrador
Bone and Bones
Tooth Extraction
Bone Morphogenetic Proteins
Bicuspid
recombinant human bone morphogenetic protein-2
Titanium
Mouth
Young Adult
Dogs

Keywords

  • BMP-2
  • Bone
  • Bone morphogenetic protein
  • Dog
  • Oral/dental implant
  • Radiology
  • Seroma
  • Tissue engineering
  • Titanium

ASJC Scopus subject areas

  • Oral Surgery

Cite this

Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2 : Radiographic observations. / Leknes, Knut N.; Yang, Jie; Qahash, Mohammed; Polimeni, Giuseppe; Susin, Cristiano; Wikesjö, Ulf M E.

In: Clinical Oral Implants Research, Vol. 19, No. 10, 01.10.2008, p. 1027-1033.

Research output: Contribution to journalArticle

Leknes, Knut N. ; Yang, Jie ; Qahash, Mohammed ; Polimeni, Giuseppe ; Susin, Cristiano ; Wikesjö, Ulf M E. / Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2 : Radiographic observations. In: Clinical Oral Implants Research. 2008 ; Vol. 19, No. 10. pp. 1027-1033.
@article{458d6bcebe86479bbb943a0142fe9915,
title = "Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: Radiographic observations",
abstract = "Objectives: Effective carrier technologies and dosing appear critical for the successful use of bone morphogenetic proteins (BMPs). This study evaluated radiographically the potential of a purpose-designed titanium porous-oxide implant surface combined with recombinant human BMP-2 (rhBMP-2) to stimulate alveolar ridge augmentation. Material and methods: Twelve young-adult Labrador dogs were used. Three 10-mm titanium implants per jaw quadrant were placed 5 mm into the alveolar ridge following extraction of the premolar teeth and reduction of alveolar ridge. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml randomized to contralateral jaw quadrants. Another six animals received implants coated with rhBMP-2 at 3 mg/ml or uncoated control using the same split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately postsurgery (baseline), and at weeks 4 and 8 (end of study). Results: rhBMP-2-coated implants exhibited robust radiographic bone formation extending to and above the implant platform from week 4 (P<0.01). Some rhBMP-2-coated implants showed voids within the newly formed bone that gradually resolved and/or implant displacement, being severe in two animals receiving implants coated with rhBMP-2 at 3 mg/ml. Controls showed limited, if any, new bone formation at weeks 4 and 8 postsurgery. There were no significant differences among the rhBMP-2 groups in bone gain. Conclusions: The titanium porous-oxide surface serves as an effective carrier for rhBMP-2, showing a clinically significant potential to stimulate local bone formation. With the carrier technology used, therapeutic dosage appears to be in the range of 0.75-1.5 mg/ml.",
keywords = "BMP-2, Bone, Bone morphogenetic protein, Dog, Oral/dental implant, Radiology, Seroma, Tissue engineering, Titanium",
author = "Leknes, {Knut N.} and Jie Yang and Mohammed Qahash and Giuseppe Polimeni and Cristiano Susin and Wikesj{\"o}, {Ulf M E}",
year = "2008",
month = "10",
day = "1",
doi = "10.1111/j.1600-0501.2008.01567.x",
language = "English (US)",
volume = "19",
pages = "1027--1033",
journal = "Clinical Oral Implants Research",
issn = "0905-7161",
publisher = "Blackwell Munksgaard",
number = "10",

}

TY - JOUR

T1 - Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2

T2 - Radiographic observations

AU - Leknes, Knut N.

AU - Yang, Jie

AU - Qahash, Mohammed

AU - Polimeni, Giuseppe

AU - Susin, Cristiano

AU - Wikesjö, Ulf M E

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objectives: Effective carrier technologies and dosing appear critical for the successful use of bone morphogenetic proteins (BMPs). This study evaluated radiographically the potential of a purpose-designed titanium porous-oxide implant surface combined with recombinant human BMP-2 (rhBMP-2) to stimulate alveolar ridge augmentation. Material and methods: Twelve young-adult Labrador dogs were used. Three 10-mm titanium implants per jaw quadrant were placed 5 mm into the alveolar ridge following extraction of the premolar teeth and reduction of alveolar ridge. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml randomized to contralateral jaw quadrants. Another six animals received implants coated with rhBMP-2 at 3 mg/ml or uncoated control using the same split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately postsurgery (baseline), and at weeks 4 and 8 (end of study). Results: rhBMP-2-coated implants exhibited robust radiographic bone formation extending to and above the implant platform from week 4 (P<0.01). Some rhBMP-2-coated implants showed voids within the newly formed bone that gradually resolved and/or implant displacement, being severe in two animals receiving implants coated with rhBMP-2 at 3 mg/ml. Controls showed limited, if any, new bone formation at weeks 4 and 8 postsurgery. There were no significant differences among the rhBMP-2 groups in bone gain. Conclusions: The titanium porous-oxide surface serves as an effective carrier for rhBMP-2, showing a clinically significant potential to stimulate local bone formation. With the carrier technology used, therapeutic dosage appears to be in the range of 0.75-1.5 mg/ml.

AB - Objectives: Effective carrier technologies and dosing appear critical for the successful use of bone morphogenetic proteins (BMPs). This study evaluated radiographically the potential of a purpose-designed titanium porous-oxide implant surface combined with recombinant human BMP-2 (rhBMP-2) to stimulate alveolar ridge augmentation. Material and methods: Twelve young-adult Labrador dogs were used. Three 10-mm titanium implants per jaw quadrant were placed 5 mm into the alveolar ridge following extraction of the premolar teeth and reduction of alveolar ridge. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml randomized to contralateral jaw quadrants. Another six animals received implants coated with rhBMP-2 at 3 mg/ml or uncoated control using the same split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately postsurgery (baseline), and at weeks 4 and 8 (end of study). Results: rhBMP-2-coated implants exhibited robust radiographic bone formation extending to and above the implant platform from week 4 (P<0.01). Some rhBMP-2-coated implants showed voids within the newly formed bone that gradually resolved and/or implant displacement, being severe in two animals receiving implants coated with rhBMP-2 at 3 mg/ml. Controls showed limited, if any, new bone formation at weeks 4 and 8 postsurgery. There were no significant differences among the rhBMP-2 groups in bone gain. Conclusions: The titanium porous-oxide surface serves as an effective carrier for rhBMP-2, showing a clinically significant potential to stimulate local bone formation. With the carrier technology used, therapeutic dosage appears to be in the range of 0.75-1.5 mg/ml.

KW - BMP-2

KW - Bone

KW - Bone morphogenetic protein

KW - Dog

KW - Oral/dental implant

KW - Radiology

KW - Seroma

KW - Tissue engineering

KW - Titanium

UR - http://www.scopus.com/inward/record.url?scp=51749087337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51749087337&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0501.2008.01567.x

DO - 10.1111/j.1600-0501.2008.01567.x

M3 - Article

C2 - 18828819

AN - SCOPUS:51749087337

VL - 19

SP - 1027

EP - 1033

JO - Clinical Oral Implants Research

JF - Clinical Oral Implants Research

SN - 0905-7161

IS - 10

ER -